Encorafenib and Cannabidiol: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Cannabidiol
Encorafenib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Reduced exposure of cannabidiol and reduced active cannabidiol metabolite exposure
Interaction Deep Dive
Concomitant use of cannabidiol (a CYP3A4 substrate) with a strong CYP3A4 inducer has resulted in reduced cannabidiol exposure as well as reduced exposure of 7-OH-CBD (active cannabidiol metabolite). Consider up to a 2-fold increase in cannabidiol dosage based on clinical response and tolerability when cannabidiol is coadministered with a strong CYP3A4 inducer1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of cannabidiol
Literature reports
1 report — tap to read
a) Coadministration of cannabidiol and rifAMPin 600 mg once daily (a strong CYP3A4 inducer) decreased cannabidiol concentrations by approximately 32%. There were moderate changes in exposure to the active metabolite 7-OH-CBD, which decreased by 63% for AUC and by 67% for Cmax. Metabolite 7-COOH-CBD also decreased by 48% for AUC, with no change in Cmax. The effects on the efficacy of cannabidiol are not known 1.
Common questions
Can I take Encorafenib and Cannabidiol together?
Reduced exposure of cannabidiol and reduced active cannabidiol metabolite exposure Always confirm with your pharmacist or prescriber before making any change.
How serious is the Encorafenib and Cannabidiol interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Encorafenib or Cannabidiol need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: EPIDIOLEX(R) oral solution, cannabidiol oral solution. Jazz Pharmaceuticals, Inc. (per FDA), Palo Alto, CA, 2025. DailyMed
Keep reading about Cannabidiol
Keep reading about Encorafenib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist